Suchergebnisse - "Banerjee, S"

PubPharm (6)

1

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus : The PARAGON trial (ANZGOG 0903)

enthalten in: Gynecologic oncology | 2021

von Edmondson, R. | O'Connell, R. | Banerjee, S. | +17

2

Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas : The PARAGON trial (ANZGOG 0903)

enthalten in: Gynecologic oncology | 2021

von Friedlander, M. | Benson, C. | O'Connell, R. | +17

3

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer

enthalten in: Gynecologic oncology | 2020

von Hall, M. | Dehbi, H. | Banerjee, S. | +11

4

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Banerjee, S. | Oza, A. | Birrer, M. | +18

5

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis : analyses from a phase 2 study in patients treated with ixekizumab

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2016

von Edson-Heredia, E. | Banerjee, S. | Zhu, B. | +6

6

Early clinical response as a predictor of subsequent response to ixekizumab treatment : results from a phase II study of patients with moderate-to-severe plaque psoriasis

enthalten in: The British journal of dermatology | 2013

von Zhu, B. | Edson-Heredia, E. | Cameron, G. | +6

CommentIn: Br J Dermatol. 2013 Dec;169(6):1178-9. - PMID 24299528

1
[1]